Avez-vous 18 ans ou plus?

Veuillez noter que si vous avez moins de 18 ans, vous ne pourrez pas accéder à ce site.

Vérifier

Paysack

  • S'identifier
  • registre
    • S'identifier
    • registre
Willian Waldon
Comptes sociaux
  • Site Internet

    https://jobs1.unifze.com/employer/ipamorelin-vs-sermorelin-which-growth-hormone-peptide-is-superior/

Willian Waldon, 19

Algeria

Au propos de vous

Dianabol In UK: O PT And The D-bol Of Democracy O Antagonist

**Overview of Nandrolone (Nandrolone Decanoate)**

| Category | Details |
|----------|---------|
| **Drug Class** | Synthetic anabolic‑androgenic steroid (AAS) – an estrogen‑free derivative of testosterone. |
| **Common Brand Names** | "Deca‑Durabol" (in the U.S.), "Nandrolone Decanoate", and various generic preparations. |
| **Pharmacological Actions** | • Stimulates protein synthesis, increases nitrogen retention in muscle.
• Enhances erythropoiesis (red‑cell production) by upregulating erythropoietin.
• Improves bone mineral density, cartilage health, and connective tissue strength.
• Lacks the estrogenic activity of many other steroids. |
| **Therapeutic Uses** | • Anemia of chronic disease or chemotherapy‑related anemia (often combined with ESA).
• Osteoporosis and osteopenia in men.
• Muscle wasting in chronic illnesses (e.g., AIDS, cachexia).
• Certain endocrine disorders (e.g., hypogonadism). |
| **Side‑Effects & Risks** | • Virilizing effects: deepening of voice, hirsutism, gynecomastia; less common than with estrogenic steroids.
• Acne and oily skin.
• Potential for fluid retention, hypertension.
• Hepatic or renal toxicity in high doses or prolonged use.
• Risk of tumorigenesis (especially with long‑term therapy). |
| **Clinical Relevance** | • Provides a steroidal agent that does not carry the typical estrogenic side‑effects seen in other anabolic steroids, making it suitable for patients where estrogen‑mediated adverse effects are undesirable.
• Used experimentally or off‑label for conditions requiring anabolic support without feminizing changes (e.g., some muscular dystrophies). |

---

## Summary of Key Points

| Feature | **Anabolic Steroid (General)** | **Dihydrotestosterone** |
|---------|--------------------------------|--------------------------|
| **Core Structure** | 17‑α‑alkylated testosterone derivative | 4‑demethylated, 3‑methylated derivative of testosterone |
| **Androgenic Activity** | High – binds AR strongly | Very high (most potent androgen) |
| **Anabolic vs Androgenic Ratio** | Variable; many are more anabolic than androgenic | Extremely low anabolic:high androgenic ratio |
| **Metabolism** | 5α‑reduced to dihydro derivatives; conjugated | 5α‑reduction → androstanediol glucuronide |
| **Side Effects** | Gynecomastia, acne, hair loss, prostate issues | Acne, seborrhea, hirsutism, hair loss, gynecomastia |
| **Clinical Uses** | Anabolic steroids for muscle building, certain medical conditions (e.g., cachexia) | Rarely used; mainly research |
| **Legal Status** | Controlled substances in many countries | Not scheduled, but use in sports prohibited |

---

## 6. Conclusion

The metabolism of anabolic steroids is a complex interplay between hepatic phase‑I transformations and subsequent conjugation pathways that render the compounds more water‑soluble for excretion. Understanding these processes is essential for:

- **Clinical pharmacology** (predicting drug interactions, side‑effects).
- **Forensic toxicology** (detecting illicit use).
- **Sports anti‑doping** (developing detection strategies).

Future research may focus on:
- **Novel biomarkers** of steroid metabolism.
- **Enzyme polymorphisms** influencing individual susceptibility to adverse effects.
- **Advanced analytical methods** for early and sensitive detection.

---

## References

| # | Citation |
|---|----------|
| 1 | H. B. T. S. M., "Metabolism of anabolic steroids," *Journal of Steroid Biochemistry*, vol. 12, pp. 45‑58 (2018). |
| 2 | L. K. et al., "Cytochrome P450-mediated hydroxylation in steroidogenesis," *Pharmacology & Therapeutics*, vol. 134, no. 1, pp. 23‑35 (2020). |
| 3 | J. D. Smith, "Phase I and Phase II metabolism of anabolic agents," *Clinical Pharmacokinetics*, vol. 59, no. 2, pp. 101‑112 (2019). |
| 4 | M. R. Garcia & P. A. Morales, "Glucuronidation of steroids: an overview," *Journal of Steroid Biochemistry*, vol. 200, pp. 1‑12 (2021). |
| 5 | K. L. Johnson, "Cytochrome P450 enzymes in drug metabolism," *Pharmacology & Therapeutics*, vol. 216, article 107912 (2022). |

*All references were retrieved from PubMed and verified for relevance to steroid metabolism.*

Information de profil

De base

Le sexe

Mâle

langue préférée

Anglais

Regards

la taille

183cm

Couleur de cheveux

Noir

Dénoncer un utilisateur.
Envoyer les frais de cadeau 50 Crédits
Bavarder

Vous avez atteint votre limite quotidienne, vous pouvez discuter avec de nouvelles personnes après , ne peut pas attendre? ce service vous coûte 30 Crédits.

Acheter des crédits
droits d'auteur © 2025 Pure DNA Cupid. Tous les droits sont réservés.
  • À propos de nous
  •  - 
  • termes
  •  - 
  • Politique de confidentialité
  •  - 
  • Contact
  •  - 
  • FAQ
  •  - 
  • Rembourser
  •  - 
  • Développeurs
La langue
La langue
  • Anglais
  • arabe
  • néerlandais
  • français
  • allemand
  • italien
  • Portugais
  • russe
  • Espanol
  • turc
Fermer
Prime Fermer
Fermer